BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld Asia
See today's BioWorld
Home
» Everest Medicines expands IgAN deal with Calliditas to include South Korea
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Everest Medicines expands IgAN deal with Calliditas to include South Korea
March 15, 2022
By
Gina Lee
No Comments
Everest Medicines Ltd. has acquired rights to develop and commercialize Nefecon (budesonide) for the treatment of primary IgA nephropathy in South Korea from Calliditas Therapeutics AB.
BioWorld
BioWorld Asia
Deals and M&A